<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Peijia Medical Ltd — News on 6ix</title>
    <link>https://6ix.com/company/peijia-medical-ltd</link>
    <description>Latest news and press releases for Peijia Medical Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 26 Mar 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/peijia-medical-ltd" rel="self" type="application/rss+xml" />
    <item>
      <title>Peijia Medical Announces 2025 Annual Results</title>
      <link>https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-announces-2025-annual-results</link>
      <guid isPermaLink="true">https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-announces-2025-annual-results</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 GMT</pubDate>
      <description>Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the year ended December 31, 2025 on March 25, 2026.</description>
    </item>
    <item>
      <title>DCwire® Micro Guidewire Receives FDA 510(k) Clearance, Marking a Key Milestone in Peijia Medical&apos;s Global Expansion</title>
      <link>https://6ix.com/company/peijia-medical-ltd/news/dcwirer-micro-guidewire-receives-fda-510k-clearance-marking-a-key-milestone-in-peijia-medicals-global-expansion</link>
      <guid isPermaLink="true">https://6ix.com/company/peijia-medical-ltd/news/dcwirer-micro-guidewire-receives-fda-510k-clearance-marking-a-key-milestone-in-peijia-medicals-global-expansion</guid>
      <pubDate>Wed, 18 Mar 2026 12:00:00 GMT</pubDate>
      <description>Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its DCwire® Micro Guidewire has received 510(k) clearance from the U.S. Food and Drug Administration (&quot;FDA&quot;) on March 17, 2026. The product was independently designed and developed by Achieva Medical Limited, a subsidiary of the Company.</description>
    </item>
    <item>
      <title>Peijia Medical Submits EU MDR CE Mark Registration Application for GeminiOne® TEER System</title>
      <link>https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-submits-eu-mdr-ce-mark-registration-application-for-geminioner-teer-system</link>
      <guid isPermaLink="true">https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-submits-eu-mdr-ce-mark-registration-application-for-geminioner-teer-system</guid>
      <pubDate>Mon, 09 Feb 2026 06:00:00 GMT</pubDate>
      <description>Peijia Medical Limited (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System for the treatment of mitral regurgitation, with HighLife SAS being the Company&apos;s European partner.</description>
    </item>
    <item>
      <title>Peijia Medical Receives NMPA Approval for TaurusTrio Transcatheter Aortic Valve System, Pioneering Treatment for Aortic Regurgitation in China</title>
      <link>https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-receives-nmpa-approval-for-taurustrio-transcatheter-aortic-valve-system-pioneering-treatment-for-aortic-regurgitation-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-receives-nmpa-approval-for-taurustrio-transcatheter-aortic-valve-system-pioneering-treatment-for-aortic-regurgitation-in-china</guid>
      <pubDate>Fri, 12 Dec 2025 12:30:00 GMT</pubDate>
      <description>Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the National Medical Products Administration (NMPA) of China on December 11, 2025.</description>
    </item>
    <item>
      <title>Peijia Medical Announces 2025 Interim Results</title>
      <link>https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-announces-2025-interim-results</link>
      <guid isPermaLink="true">https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-announces-2025-interim-results</guid>
      <pubDate>Mon, 25 Aug 2025 12:00:00 GMT</pubDate>
      <description>Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months ended June 30, 2025 (&quot;the Reporting Period&quot;) on August 22, 2025.</description>
    </item>
    <item>
      <title>Peijia Medical Announces 2024 Annual Results</title>
      <link>https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-announces-2024-annual-results</link>
      <guid isPermaLink="true">https://6ix.com/company/peijia-medical-ltd/news/peijia-medical-announces-2024-annual-results</guid>
      <pubDate>Wed, 26 Mar 2025 12:00:00 GMT</pubDate>
      <description>Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the year ended December 31, 2024 (&quot;the Year&quot;) on March 25, 2025.</description>
    </item>
  </channel>
</rss>